Search Science Hub

Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

Achievement of HbA1c and body weight loss composite endpoints with once-weekly semaglutide 2.0 mg versus 1.0 mg in T2D: post-hoc analysis from SUSTAIN FORTE

Authors :

Harpreet S. Bajaj¹; Chethana KR²; Thomas P. Gunnarsson³; Suvanjaa Sivalingam³; Nikolaos Tentolouris⁴; John Buse⁵

Affiliations

View Details Hide Details

Download poster (.pdf)

Keywords

Diabetes

Congress short oral presentation

GLP-1 RA

Semaglutide

Clinical